Home Small Molecules Discovery Biology Integrated In Vivo Pharmacology Immuno Oncolgy & In Vitro Pharmacology

Immuno Oncolgy & In Vitro Pharmacology

Syngeneic models for checkpoint inhibitor efficacy, immune cell profiling, cell-based assays, target engagement, and translational biomarkers.

Immuno-Oncology In Vivo

9 validated syngeneic tumor models for immunocompetent efficacy studies
Checkpoint inhibitor (PD-1, PD-L1, CTLA-4) efficacy assessment
Immune cell infiltration and activation profiling (flow cytometry)
Tumor microenvironment characterization
Biomarker identification for patient stratification
Combination studies (checkpoint inhibitor + targeted therapy)
Advanced readouts: PD-L1 expression, T-cell proliferation, immune memory

In Vitro Pharmacology Capabilities

Cell-based assays (recombinant systems, native cellular, tissue models)
Target engagement (FRET, HTRF, fluorescence polarization)
Receptor pharmacology (GPCRs, ion channels, enzymes)
High-content imaging and phenotypic screening
3D tumor models and organoid platforms
Immune cell assays (T-cell activation, cytokine profiling)
Biomarker profiling (MSD, ELISA, Luminex)